Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 108 mg solution for injection in pre-filled pen
VedolizumabSC-3004
Phase 3 small_molecule active
Quick answer
Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 108 mg solution for injection in pre-filled pen for Ulcerative Colitis or Crohn’s Disease is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Ulcerative Colitis or Crohn’s Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active